Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: Results of a first feasibility and case control study;Zytoreduktive radikale Prostatektomie beim Prostatakarzinom mit minimaler ossärer Metastasierung: Ergebnisse einer ersten Machbarkeits- und Fall-Kontroll-Studie

Urologe

Volumn 54, Issue 1, 2015, Pages 14-21

  Heidenreich, A ^a   Pfister, D ^a   Brehmer, B ^a   Porres, D ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Androgen deprivation; Bone metastases; Hydronephrosis; Neoadjuvant therapy; Nephrostomy, percutaneous

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; BONE NEOPLASMS; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; FEASIBILITY STUDY; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; CASE-CONTROL STUDIES; CYTOREDUCTION SURGICAL PROCEDURES; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84925490649     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-014-3697-8     Document Type: Article

References (29)

1. Heidenreich A, Bastian PJ, Bellmunt J et al (2013) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124
2. Alemayehu B, Buysman E, Parry D et al (2010) Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 13:351
3. Won AC, Gurney H, Marx G et al (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:250
4. Aus G, Hugosson J, Norlén L (1995) Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 154(2 Pt 1):466
5. Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta- analysis. J Clin Oncol 20:1248
6. Nitta T, Sato K (1995) Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75:2727
7. Temple LK, Hsieh L, Wong WD et al (2004) Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475
8. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655
9. Mickisch GH, Garin A, Poppel H van et al (2001) Radical nephrectomy plus interferon-alfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966
10. Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER- based study. Eur Urol 65:1058
11. Tzelepi V, Efstathiou E, Wen S et al (2011) Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29:2574
12. Comen E, Norton L, Massague J (2011) Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 8:369
13. Predina JD, Kapoor V, Judy BF et al (2012) Cytoreduction surgery reduces myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol 5:34
14. Heidenreich A, Knobloch R von, Varga Z (2001) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy in prostate cancer: high incidence of lymph node metastases. J Urol 167:1681
15. Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467
16. Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036
17. Glass TR, Tangen CM, Crawford ED et al (2003) Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 169:164–169
18. Hussain M, Tangen CM, Higano C et al (2006) Southwest Oncology Group Trial 9346 (INT- 0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984
19. Steuber T, Budäus L, Walz J et al (2011) Radical prostatectomy improves progression-free and cancer specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 107:1755
20. Spahn M, Joniau S, Gontero P et al (2010) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1
21. Crain DS, Amling CL, Kane CJ (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171(2 Pt 1):668
22. Studer UE, Whelan P, Albrecht W et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24:1868
23. Steinberg GD, Epstein JI, Piantadosi S et al (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144:1425
24. Thompson IM, Tangen C, Basler J, Crawford ED (2002) Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168:1008
25. Gjertson C, Asher K, Sclar J et al (2007) Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 70:723
26. Grimm M-O, Kamphausen H, Hugenschmidt H et al (2012) Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 41:628
27. Qin XJ, Ma CG, Ye DW et al (2012) Tumor cytoreduction results in better response to androgen ablation – a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol 30:145
28. Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62(1):68–75
29. Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imag 40(4):486–495